Sunday, February 25, 2024
Arabic Arabic Bengali Bengali English English French French Hindi Hindi Indonesian Indonesian Malay Malay Punjabi Punjabi Russian Russian Spanish Spanish Turkish Turkish Urdu Urdu

Intellasia East Asia News – AstraZeneca vaccine turns profitable, drugmaker banking on new orders

Must Read

March 2024: Psychic Insights for Each Birth Number |

Number 1 (Born on 1st/ 10th/ 19th/ 28th of any month)Number 1 is ruled by planet Sun. People born...

Weekly Love Horoscope, February 11 to February 17, 2024 |

Aries Single Aries can make a connection with someone they haven't seen in a long time when searching for...

Pisces Horoscope Today: Embrace the Flow of Your Emotions and Creativity |

Today, Pisces, the cosmos envelops you in a wave of creativity and empathy, highlighting your intuitive and artistic talents....


AstraZeneca’s (AZN.L) COVID-19 vaccine made a small contribution to earnings in the third quarter and it expects the shot to move to “modest profitability” on new orders after the drugmaker on Friday posted $1.05 billion in vaccine sales for the period.

The Anglo-Swedish company, which has said will not make a profit from the cheap and easy-to-use shot during the pandemic, this week unveiled plans to set up a separate unit for vaccines and antibody treatments to focus on its coronavirus efforts.

Total revenue jumped 47 percent to $9.74 billion for the three months to September on a constant-currency basis, while core earnings came in at $1.08 per share, the company said, with the vaccine, Vaxzevria, contributing one cent to the profit.

The addition of rare-disease specialist Alexion from July 21, thanks to a $39 billion deal agreed almost a year ago, also boosted sales.

Analysts on average were expecting profit of $1.28 per share on sales of $9.4 billion, according to Refinitiv IBES data.

Some of the company’s core treatments for cancer, rare-diseases and heart conditions disappointed, with lower-than-expected growth in sales of lung cancer drug Tagrisso due to price cuts in China.

However, established asthma drug Symbicort recorded a strong performance in emerging markets, with sales overall up 13 percent at $676 million in the quarter. Revenues of the best-seller Tagrisso rose 8 percent to $1.25 billion.

AstraZeneca said the limited profit from the vaccine in the fourth quarter would make up for costs related to its antibody cocktail for preventing and treating COVID-19, as it stuck with its overall forecasts for the year.

Rival Pfiser (PFE.N) this month forecast 2021 and 2022 sales from its COVID-19 vaccine of at least $65 billion overall, topping estimates. However, Moderna (MRNA.O) slashed its 2021 sales outlook for its shot by as much as $5 billion, on production hiccups.

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-makes-over-1 billion-q3-vaccine-sales-small-profit-2021-11-12/

 

Category: Health


Print This Post


- Advertisement -
- Advertisement -

Latest News

March 2024: Psychic Insights for Each Birth Number |

Number 1 (Born on 1st/ 10th/ 19th/ 28th of any month)Number 1 is ruled by planet Sun. People born...
- Advertisement -

More Articles Like This

- Advertisement -